JAK2 and myeloproliferative disorder: Overall, these observations strengthen the view that, in JAK2-V617F-positive MPN, dysregulated activation of integrins on neutrophils/monocytes, platelets, and erythrocytes leads to abnormal integrin-mediated interaction of circulating blood cells with endothelial cells.